上海起發實驗試劑正規代理Trilink產品，zui近市場出現Trilink的假貨，為了您的實驗安全請選擇正牌代理。 :

TriLink BioTechnologies——高品質常規/特殊核苷酸產品
TriLink BioTechnologies公司是世界的核酸修飾技術領域的，成立于1996年，總部設在San Diego，California。TriLink公司致力于高品質核酸修飾產品的研發和生產，提供包括核苷酸、常規及核苷三磷酸特殊修飾的寡核苷酸定制（oligonucleotides），m RNA合成，CleanAmp?PCR產品，phosphoramidites和其他小分子在內的眾多產品。近二十年來，TriLink一直是診斷和OEM市場核酸產品供應的行業，產品應用于基因治療，核苷類化療，寡核苷酸治療和診斷領域。此外，TriLink還可提供特殊核苷酸、m RNA定制，合同研究服務和ISO/ QSR標準的cGMP生產設施。TriLink完善的產品及研發服務解決方案有助于推動藥物發現和生物醫學研究。

經過18年的發展， TriLink已經成為高品質RNA合成領域的，為廣大科研工作者提供的mRNA及長鏈RNA（長可達幾個Kb），并且定制修飾。同時我們也提供成品mRNA產品，包括報告基因及 mRNA表達因子。

Antigen mRNA for Vaccines and Immunotherapy

mRNA offers several advantages over traditional plasmid and viral-based approaches:

• mRNA boasts a superior safety profile. As a transient carrier of genetic information, it is metabolized naturally and poses little to no risk of genomic integration. Additionally, no inactivated viruses or pathogens are needed.
• mRNA serves the dual purpose of expressing the desired antigen as well as acting as an adjuvant.
• mRNA triggers a more diverse immune response. Because the mRNA encoded epitopes are intracellular, they are recognized by the immune system in an MHC class-independent manner.
• mRNA can more readily transfect difficult-to-transfect cell types because it functions in the cytoplasm. DNA vaccines can be limited by lack of access to the nucleus.
• mRNA manufacturing is easily scalable. Because mRNA transcription is carried out compley in vitro, to hundreds of millions of vaccine doses with a lead time of as little as a few weeks. This allows for rapid deployment of a new antigen during pandemics.
• mRNA is easily customizable. The ease of manufacturing makes it a viable option for personalized treatments.

產品如下:

L-7210
CleanCap™ OVA mRNA (5moU)
CleanCap™ Ovalbumin mRNA (5-methoxyuridine) 


 

mRNA Length: 1,437 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

Product Insert
SDS

Ovalbumin (OVA) is a member of the serpin superfamily and the predominant glycoprotein found in egg whites. It is a commonly used antigen for immunization and biochemical studies and is an established model allergen for airway hyper-responsiveness.

This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.

TriLink offers both unmodified and 5-methoxyuridine modified OVA mRNA. Exogenous unmodified mRNA activates the innate immune system and production of cytokines, which will influence the overall induced immune response. mRNA modified with 5-methoxyuridine reduces this effect.
 

Certificate(s) of Analysis

TD-OB06A

L-7210 is a replacement for L-6128,

Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.

L-7610
CleanCap™ OVA mRNA
CleanCap™ Ovalbumin mRNA 




 

mRNA Length: 1,437 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

Product Insert
SDS

Ovalbumin (OVA) is a member of the serpin superfamily and the predominant glycoprotein found in egg whites. It is a commonly used antigen for immunization and biochemical studies and is an established model allergen for airway hyper-responsiveness.

This mRNA is capped using CleanCap™, TriLink’s proprietary co-transcriptional capping method,

which results in the naturally occurring Cap 1 structure with high capping efficiency. It is polyadenylated and optimized for mammalian systems. It mimics a fully processed mature mRNA.

TriLink offers both unmodified and 5-methoxyuridine modified OVA mRNA. Exogenous unmodified mRNA activates the innate immune system and production of cytokines, which will influence the overall induced immune response. mRNA modified with 5-methoxyuridine reduces this effect.

Certificate(s) of Analysis

TD-OB07A

L-7610 is a replacement for L-6328.

Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.